Backed by Top-notch Life Science Investors

SanReno’s second core asset, BION-1301, as an anti-APRIL monoclonal antibody which is currently in Phase 1/2 clinical trial evaluating its efficacy of IgAN. Chinook released the interim data for the Phase 1/2 trial at the American Society of Nephrology (ASN) meeting in November 2021. 4 of the IgAN patients completed 6-month intravenous injection (450 mg/every 2 weeks) of BION-1301. The data showed about 60% of proteinuria decrease compared with baseline, as well as a 70%-80% decrease in IgA and pathogenic gd-IgA1. The patient tolerated BION-1301 well with no serious adverse events occurred during treatment. The data shows that BION-1301 has the chance to become an innovative and disease-modifying drug of IgAN, thereby changing the current landscape of limited treatment in IgAN.

Pivotal bioVenture Partners China, a member of Nan Fung Life Sciences, is a venture capital firm specializing in venture building in the life sciences industry.

The Pivotal China investment strategy is centered on identifying promising innovative products and technologies and bringing them to serve the growing unmet medical needs in Greater China region by building new ventures. Its investment areas include therapeutics, medical devices and medical services.

The Pivotal China team includes experienced life science investors and entrepreneurs with successful track records of venture building and investing. For more information about Pivotal bioVenture Partners China, please refer to www.pivotalbiovp.com

Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With over $7.1 billion total capital raised, Frazier has invested in more than 200 companies, with investment types ranging from company creation and venture capital to publicly traded companies and buyouts of profitable lower-middle market companies.

Headquartered in Menlo Park, Calif., the Frazier Life Sciences team invests globally in private and publicly traded companies that develop and commercialize innovative biopharmaceuticals to address important unmet medical needs. Since 2005, 61 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier, have completed IPOs or M&As.

www.frazierhealthcare.com/life-sciences

Samsara BioCapital was founded after years of working in the medical field and investment industry. The goal of Samsara is to help entrepreneurs turn their own ideas and visions into successful companies with fundraising and networking guidance. As a results-driven organization, we are constantly looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level.

Samsara BioCapital are horrified by and mourn the senseless and vicious murder of George Floyd, and many other innocent men and women of color, by the police over the years, but also inspired by (and join) the protesters who have been marching over the last two weeks against the systemic racism that has plagued the US. The militarization of the police and their targeting of Blacks have criminalized skin color and dehumanized a vast segment of the American population – it is well past time to end these ingrained disgusting practices. Samara are heartened to see the shedding of complacency by the populace, as well as some signs of policy movement regarding acceptable police actions and immunity in Washington. However, progress along many more fronts is required to eliminate the purposefully built-in societal disadvantages that treat Blacks as second class citizens and keep them repressed.

Samsara stands with all those who fight for true equality and fairness – they are fortunate to be given the amazing gift of life in an incredible time, and they should all be treated with equal, unmitigated importance.

www.samsaracap.com

Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders.